Regeneron Expands Bispecifics, Gene Therapy Programs As Exec Hints At More Deals
The drug maker reported what it said were encouraging early uptake signs for Eylea HD while also seeking to reassure analysts concerned about its BCMA-directed bispecific’s differentiation.
You may also be interested in...
The cell therapy biotech will reduce its headcount from 280 to 65, with most of them – including two execs – going to Regeneron, which is paying just $5m up front to become a cell therapy player.
Biosimilar aflibercept rivals to Eylea are advancing towards approval, with Formycon reporting EMA acceptance of its filing for its FYB203 version and Alvotech disclosing positive trial results for its AVT06 candidate.
The BCMAxCD3-directed bispecific for multiple myeloma is one of the crown jewels of Regeneron’s larger program to develop bispecifics as it diversifies beyond its traditional core franchises.